Market revenue in 2023 | USD 72.3 million |
Market revenue in 2030 | USD 115.6 million |
Growth rate | 6.9% (CAGR from 2023 to 2030) |
Largest segment | Toxicology testing |
Fastest growing segment | Bioanalysis and DMPK studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Toxicology testing was the largest segment with a revenue share of 26.14% in 2023. Horizon Databook has segmented the Italy preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
The pharmaceutical sector remains a major development driver for the Italian economy. The increasing demand for drugs and the simplified approval process for clinical trials on new medicines have aided in the significant growth of the Italian pharmaceutical industry. The biotech companies of Italy are focusing on oncology and various other diseases, including infectious diseases, cardiovascular, neurological, and inflammatory.
Recent reemergence of infectious diseases, such as COVID-19 increased investments in developing new treatments. Such actions are likely to profit the market in Italy. The large number of emerging CROs offering a variety of services in Italy, especially in preclinical research, is expected to boost the country’s market.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account